MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.Read More
Recent Press Releases
09/21/16MyoKardia Outlines Path to Registration for MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients and Provides Pipeline and Research Updates at Inaugural R&D Day
NASDAQ GS | MYOK (Common Stock)
$16.34 + 0.34
09/30/164:00 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
There are currently no events scheduled.